IDEXX (IDXX) Stock Looks Fair On Cash Flow But Rich On Earnings
IDEXX Laboratories has had a weak run over the past five years, yet the current checks suggest the stock is not obviously cheap, with the Discounted Cash Flow (DCF) estimate pointing to a price close to intrinsic value while market multiples lean expensive. That mix leaves investors weighing a fairly valued intrinsic view against richer headline valuation ratios.
- IDEXX Laboratories has delivered a decline of 15.7% over five years, which softens the long term return story even before looking at today’s valuation.
- The expansion of IDEXX’s Catalyst platform into in clinic cardiac testing can support expectations for recurring diagnostics revenue, while any disappointment around future growth or margins may weigh heavily given the current pricing.
- With a low valuation score of 2 out of 6 checks, IDEXX Laboratories currently looks like a stock that leans expensive rather than a clear bargain on the broader tests.
The issue now is whether a stock that screens as fairly valued on intrinsic value but expensive on multiples still offers a compelling entry point for IDEXX Laboratories at today’s price.
Find out why IDEXX Laboratories' -14.1% return over the last year is lagging behind its peers.
Is IDEXX Laboratories Fairly Priced on Cash Flow?
The Discounted Cash Flow (DCF) method estimates what IDEXX Laboratories is worth based on the cash it can generate for shareholders over time. For IDEXX Laboratories, the model uses last twelve month free cash flow of about $1.22b and assumes that cash flows keep growing from this base rather than shrinking.
On these projections, the DCF points to an intrinsic value of about $596 per share. This sits only slightly above the current market price and implies the stock is roughly 4.3% undervalued. The recent launch of the Catalyst proBNP cardiac test helps explain why the market is comfortable paying close to the cash flow based estimate.
Overall, the cash flow model suggests IDEXX Laboratories stock is approximately fairly valued at current levels.
IDEXX Laboratories is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.
Is IDEXX Laboratories Getting Expensive on Earnings?
The P/E ratio fits IDEXX Laboratories well because earnings are a key focus for how investors are pricing the stock today. IDEXX Laboratories currently trades on a P/E of about 39.4x, which is well above the Medical Equipment industry average of 26.4x and also above a peer group average of 30.7x. That already places the stock at a clear premium to many other companies in the sector.
The tailored fair P/E ratio for IDEXX Laboratories is calculated at about 29.3x, based on its growth profile, margins, size and risk. Compared with the current 39.4x, the gap is sizeable and indicates that investors are paying more than this framework would suggest. On this measure, the earnings multiple appears stretched rather than aligned with the broader benchmarks.
On the P/E multiple, IDEXX Laboratories stock currently screens as overvalued.
See what the numbers say about this price — find out in our valuation breakdown.
The IDEXX Laboratories Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for IDEXX Laboratories help you connect the DCF and P/E signals above with the specific future paths that would make the stock meaningfully more or less attractive at today's price. They are available on the company’s Community page. Where a single ratio or model gives you one number, these narratives spell out the underlying assumptions on growth, margins and earnings so you can see what needs to play out and monitor whether that picture is holding up over time.
Community views on IDEXX Laboratories sit wide apart, with one side focused on recurring diagnostics strength and the other on demand and pricing risk.
Bull case: 20% undervalued
"High customer retention and growing installed base of premium instruments provide IDEXX with stable, high-margin recurring revenue streams, positioning the company to compound earnings growth over time as industry consolidation and elevated care standards continue…"
Read the full Bull Case to see why IDEXX Laboratories could be undervalued
Bear case: 8% overvalued
"Persistently weak clinic visit volumes in the U.S., highlighted by a 2.5% quarterly decline in same-store clinical visits, may become the norm as economic pressures and shifting consumer priorities make pet owners more price sensitive, suppressing adoption of higher-margin diagnostics and reducing both revenue and net margins over time…"
Read the full Bear Case to see why IDEXX Laboratories could be overvalued
Do you think there's more to the story for IDEXX Laboratories? Head over to our Community to see what others are saying!
The Bottom Line
For IDEXX Laboratories, the Discounted Cash Flow (DCF) view points to a share price close to intrinsic value, so the stock does not screen as a clear bargain on cash flows alone. The P/E based view, by contrast, suggests the stock is overvalued relative to both peers and a tailored fair multiple, and this aligns with the low overall value score. That gap mostly reflects how strongly the market is pricing in growth and margin durability on top of solid cash generation. The real swing factor from here is whether IDEXX can sustain the diagnostics growth and profitability that investors are already paying up for.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com